ARCUTIS BIOTHERAPEUTICS, INC.
ARQTLoading price...
Overview
Previous Close--
Open--
Ask--
Bid--
Day's Range-- - --
52 Week Range-- - --
PE Ratio(TTM)--
Market Cap--
Volume--
Avg. Volume--
12 Months Earnings28.52M
12 Months Revenue463.98M
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 463.98M | 376.07M | 263.46M | 196.54M | 59.61M | 3.69M |
| Cost of Revenue | 41.10M | 36.70M | 28.73M | 19.13M | 4.99M | 754.00k |
| Gross Profit | 422.88M | 339.38M | 234.74M | 177.41M | 54.62M | 2.93M |
| Operating Expenses | 388.63M | 351.60M | 320.57M | 305.81M | 295.72M | 304.56M |
| Profit after Tax (Net Income) | 28.52M | -16.14M | -93.27M | -140.04M | -262.14M | -311.46M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Westlake Village, United States
Website: https://www.arcutis.com
President, CEO & Director: Mr. Todd Franklin Watanabe M.A.
Employees: 354
About Company:
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.